Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Graft vs Host Disease 1

Interventions

Specimen Handling 22fludarabine 20Cyclophosphamide 19Biopsy 19fludarabine phosphate 15Cytarabine 13Whole-Body Irradiation 11Busulfan 11Tacrolimus 10Mycophenolic Acid 10Melphalan 10venetoclax 9X-Rays 9decitabine and cedazuridine drug combination 8Magnetic Resonance Spectroscopy 8Injections 8asciminib 7Granulocyte Colony-Stimulating Factor 7Cyclosporine 7ruxolitinib 6Thiotepa 6Sirolimus 6Nuclear Medicine Department, Hospital 6Azacitidine 6Stem Cell Transplantation 5Phantoms, Imaging 5Peripheral Blood Stem Cell Transplantation 5Idarubicin 5Filgrastim 5CPX-351 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Emapalumab × Myeloid × 30 days × Clear all
NCT06996119 2026-05-11

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

City of Hope Medical Center

Phase 1 Recruiting
15 enrolled
MyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡